SMTL ID : 7aei.1

Studies Towards a Reversible EGFR C797S Triple Mutant Inhibitor Series

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 2.65 Å

Oligo State

monomer

Ligands

1 x R85: 5-chloranyl-~{N}2-[4-[4-(dimethylamino)piperidin-1-yl]-2-methoxy-5-(1-methylpyrazol-4-yl)phenyl]-~{N}4-(2-dimethylphosphorylphenyl)pyrimidine-2,4-diamine(Non-covalent)

R85.1: 19 residues within 4Å: Chain A: L.25, G.26, F.30, V.33, A.50, K.52, T.97, Q.98, L.99, M.100, P.101, G.103, C.104, D.107, E.111, R.148, L.151, T.161, D.162 8 PLIP interactions: 8 interactions with chain A Hydrophobic interactions: A:L.25, A:L.25, A:F.30, A:V.33 Hydrogen bonds: A:K.52, A:M.100, A:M.100 Salt bridges: A:E.111

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Floch, N. et al., Abstract 4451: Evaluation of the therapeutic potential of phosphine oxide pyrazole inhibitors in tumors harboring EGFR C797S mutation. Cancer Res. (2019)

Release Date

2021-06-02

Peptides

Epidermal growth factor receptor: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

Epidermal growth factor receptor

Related Entries With Identical Sequence